Ian Bellayr, PhD

Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Bethesda, Maryland, United States

Disclosure(s): No financial relationships to disclose

Presentation(s):

• 593 - Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of the Safety of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine

  Saturday, October 19, 2024
  2:00 PM – 2:15 PM US PT